This article is more than 5 years old. Information may no longer be current.
Phase 2 trials demonstrate efficacy of punctal plug in lowering IOP
Click Here to Manage Email Alerts
Two multicenter phase 2 clinical trials demonstrated the safety and efficacy of QLT’s latanoprost punctal plug delivery system in patients with ocular hypertension and open-angle glaucoma, according to a press release from QLT.
“Results from our PPL GLAU 12 and PPL GLAU 13 clinical trials suggest that clinically relevant IOP lowering beyond 4 weeks may be achievable with a sustained release ophthalmic drug delivery system,” Jason Aryeh, QLT board chairman, said in the release.
In PPL GLAU 12, plugs delivering a combined total of 141 µg or 90 µg of latanoprost were simultaneously placed in the upper and lower puncta of 57 patients. In PPL GLAU 13, 95 µg of latanoprost was delivered via three different plug placement configurations in 77 patients.
Three of the trials’ five treatment arms demonstrated clinically significant IOP lowering of at least 5 mm Hg at 4 weeks, the release said.
The plugs were well tolerated throughout the testing period, with adverse events similar to those reported for commercially available punctal plugs, according to the release.